Abu Dhabi, UAE — The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial fibrillation (AF) looks as though it’s settled. Results of the ...
ORLANDO, Florida — Combining aspirin and direct oral anticoagulant (DOAC) therapy for the secondary prevention of venous thromboembolism (VTE) or the prevention of stroke associated with nonvalvular ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
In a recent study published in JAMA Network Open, researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models to prevent anticoagulation-associated adverse effects ...
Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...
To analyze the primary outcomes, DOAC users were matched 1:1 without replacement to a warfarin user. The primary effectiveness outcome was a composite of ischemic stroke or SE. Primary safety outcome ...
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma. Safety and efficacy outcomes in immune checkpoint inhibitor (ICI) ...
The direct oral anticoagulants edoxaban, apixaban, rivaroxaban and dabigatran have been recently approved for the treatment of non-valvular atrial fibrillation The new direct oral anticoagulants ...
Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results